(Q46199113)

20 December 2017

title

Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer (English)

1 reference

20 December 2017

1 reference

Guido Fechner

1

1 reference

20 December 2017

Katarina Classen

2

1 reference

20 December 2017

Doris Schmidt

3

1 reference

20 December 2017

Stefan Hauser

4

1 reference

20 December 2017

Stefan C Müller

5

1 reference

20 December 2017

language of work or name

English

0 references

publication date

11 December 2008

1 reference

20 December 2017

published in

Urology

1 reference

20 December 2017

volume

73

1 reference

20 December 2017

issue

3

1 reference

20 December 2017

page(s)

665-8; discussion 668-9

1 reference

20 December 2017

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

Targeted therapies in bladder cancer--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.09.070

10.1016/J.UROLOGY.2008.09.070

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

PubMed ID

19081609

1 reference

20 December 2017